Epicutaneous immunization of T cell receptor (TCR) transgenic (Tg) mice whose CD4 ؉ T cells are specific for the Ac1-11 fragment of myelin basic protein (MBP) with Ac1-11 elicits T cells with dominant suppressor͞regulatory activity that confers protection against Ac1-11-induced experimental autoimmune encephalomyelitis. We now report that such disease-resistant MBP TCR Tg mice also harbor a sizeable fraction of peripheral CD4 ؉ T cells lacking surface expression of the Tg TCR ␤ chain and expressing diverse, endogenously rearranged TCR ␤ chains. Ex vivo incubation at physiological temperature caused the loss of neo-␤-chain expression and reversion to the MBP ␣␤ TCR ؉ phenotype. The presence of recombination activating gene 1 and 2 proteins in CD4 ؉ T cells with revised TCRs was consistent with effective V(D)J recombination activity. The emergence of these cells did not depend on the thymic compartment. We conclude that in mice epicutaneously immunized with an autoantigen, peripheral specific T cells are susceptible to multiple mechanisms of tolerance.
Epicutaneous immunization of T cell receptor (TCR) transgenic (Tg) mice whose CD4 ؉ T cells are specific for the Ac1-11 fragment of myelin basic protein (MBP) with Ac1-11 elicits T cells with dominant suppressor͞regulatory activity that confers protection against Ac1-11-induced experimental autoimmune encephalomyelitis. We now report that such disease-resistant MBP TCR Tg mice also harbor a sizeable fraction of peripheral CD4 ؉ T cells lacking surface expression of the Tg TCR ␤ chain and expressing diverse, endogenously rearranged TCR ␤ chains. Ex vivo incubation at physiological temperature caused the loss of neo-␤-chain expression and reversion to the MBP ␣␤ TCR ؉ phenotype. The presence of recombination activating gene 1 and 2 proteins in CD4 ؉ T cells with revised TCRs was consistent with effective V(D)J recombination activity. The emergence of these cells did not depend on the thymic compartment. We conclude that in mice epicutaneously immunized with an autoantigen, peripheral specific T cells are susceptible to multiple mechanisms of tolerance.
CD4 T cells ͉ tolerance ͉ skin ͉ recombination T he direct application of purified protein antigen onto the epidermis of mice, or epicutaneous immunization (ECi), is capable of inducing a potent adaptive immune response biased toward the so-called type 2 of CD4 ϩ T helper (Th) cell response, that is, helper T cells with prominent secretion of antiinflammatory cytokines (1) (2) (3) . Hypothesizing that ECi with purified forms of autoantigens might then interfere with the development of Th1 CD4 ϩ T cell-driven proinflammatory autoimmune disorders, we previously applied the Ac1-11 fragment of myelin basic protein (MBP) to the skin of mice transgenic (Tg) for the rearranged ␣ and ␤ chain of the Ac1-11:I-A u complex-specific MBP T cell receptor (TCR) (MBP ␣␤ TCR Tg mice) (4, 5) . Because of the principle of allelic exclusion (6) (7) (8) (9) (10) ) that operates at the TCR chain loci, such engineered mice harbor a T cell repertoire dominated by the MBP ␣␤ TCR, yet not strictly monoclonal, because allelic exclusion is not absolute, particularly at the TCR ␣-chain locus. TCR chains encoded by endogenously rearranged TCR genes can thus be found on T cells from TCR Tg mice. MBP TCR Tg mice, as well as other TCR Tgs (11) , are commonly used to study experimental autoimmune encephalomyelitis (EAE), a chronic proinflammatory autoimmune pathology that targets the white matter of the CNS and serves as an animal model for the human disease multiple sclerosis (12) . We have observed that MBP TCR Tg mice epicutaneously immunized with pure Ac1-11 in the absence of any adjuvant are resistant to EAE that can be normally induced upon standard immunization with Ac1-11 plus adjuvant (13) . Interestingly, rather than involving immune deviation from the classical Th1 profile that prevails in mice with clinical signs of EAE, disease protection was mediated by CD4 ϩ T cells that acquired regulatory͞suppressor capacity. Such suppressor T cells did not produce major antiinflammatory cytokines and could confer protection to unmanipulated hosts upon adoptive transfer, indicating that suppression was dominant. Importantly, ECi with other CNS antigens could protect non-TCR Tg mice from relapsing-remitting forms of EAE, as well (13).
We report here that, in addition to induction of CD4 ϩ T cells with suppressive activity, ECi of MBP TCR Tg mice with only purified Ac1-11 endowed peripheral, specific CD4 ϩ T cells with the capacity to replace the MBP TCR ␤ chain by a diverse set of endogenously produced ␤ chains, leading to revision of the surface-expressed TCR. The data point to a model where the epicutaneous delivery of autoantigens makes peripheral T cells susceptible to multiple mechanisms of tolerance to selfdeterminants.
Materials and Methods
Mice. MBP TCR Tg mice (MBP TCR Tg ϩ/Ϫ ) express the rearranged genes encoding the ␣ (V␣4 ϩ ) and ␤ (V␤8.2 ϩ ) chains of an autoreactive, I-A u -restricted TCR specific for the acetylated N-terminal peptide (Ac1-11) of MBP. MBP TCR Tg (Thy1.1 or Thy1.2) mice were mated to TCR C␣ Ϫ/Ϫ or to rag2 Ϫ/Ϫ mice to generate MBP TCR C␣ Ϫ/Ϫ and MBP TCR rag2 Ϫ/Ϫ mice, respectively. Four-week-old to 1-month-old adult thymectomized B10.PL(H2 u ) mice were purchased from The Jackson Laboratory. All mice were bred and housed in the pathogen-free mouse facility at the Section of Immunobiology at Yale University.
Antibodies and FACS Sorting. Cells were stained with anti-CD4-FITC conjugate or anti-CD4-phycoerythrin (PE) (Caltag, South San Francisco, CA); anti-CD4-CyChrome; anti-V␤8. 1͞2-FITC͞  PE; anti-TCRC␤-PE; anti-CD69-PE; anti-CD44-PE; anti-V␤2,  3, 4, 6 Western Blotting. Cell lysates were obtained from sorted CD4 ϩ V␤8.2 ϩ or CD4 ϩ V␤8.2 Ϫ cells from Ac1-11 epicutaneously immunized mice or controls. Aliquots (10 g) of each cell lysate were run on SDS͞PAGE under reducing conditions and transferred to a transblot transfer medium nitrocellulose membrane (Bio-Rad). Blocking was with 5% milk for 2 h at room temperature. Membranes were incubated for 3 h with polyclonal antibodies against recombination-activating gene (RAG) 1 and RAG2 proteins by using specific polyclonal antibodies (a gift from D. Schatz, Yale University). The blots were washed three times with PBS plus 0.1% Tween 20. Protein bands were visualized by using secondar y horseradish peroxidaseconjugated antibodies and the ECL detection system (Amersham Biosciences) according to the manufacturer's instructions.
Results
Endogenous TCR ␤-Chain Expression in Peripheral CD4 ؉ T Cells from MBP TCR Tg Mice. MBP TCR Tg mice that are epicutaneously immunized with the cognate (Ac1-11) peptide are resistant to EAE induction. MBP TCR Tg mice that lack surface expression of the endogenously rearranged TCR ␣ chains (MBP TCR Tg C␣ Ϫ/Ϫ mice) are well known for their spontaneous and rapid development of EAE, and these mice could also be protected from disease upon ECi. Such resistance relied on the induction of CD4 ϩ T cells with dominant suppressive͞regulatory activity (13) . Disease-resistant MBP TCR Tg or MBP TCR Tg C␣ Ϫ/Ϫ mice will be referred to hereafter as Ac1-11 ECi mice. The phenotypic analysis of peripheral blood, spleen, or lymph node CD4 ϩ T cells from Ac1-11 ECi mice revealed that a sizeable fraction of them stained negative for V␤8.2, that is, for the V domain used by the transgene-encoded TCR ␤ chain ( Fig. 1 A  and B ). This fraction varied from mouse to mouse and could comprise 50% of CD4 ϩ T cells, or more, over time. This percentage was in sharp contrast with the low frequency (2-4%) of CD4 ϩ V␤8.2 Ϫ T cells detected in unmanipulated MBP TCR Tg mice and with the virtual absence of these cells in MBP TCR Tg C␣ Ϫ/Ϫ mice ( Fig. 1 C and D) . The accumulation of CD4 ϩ V␤8.2 Ϫ T cells was detected exclusively in mice that were epicutaneously immunized with Ac1-11 and immunized with Ac1-11 plus adjuvant for disease induction. In addition, the increase in frequency of CD4 ϩ V␤8.2 Ϫ T cells was never observed in MBP TCR Tg mice that were epicutaneously immunized with vehicle (PBS), an irrelevant antigen (ovalbumin), or a CNS antigenic peptide other than Ac1-11 (such as MOG 35-55) before Ac1-11 challenge (Fig. 1E) TCR ␤ chain(s) in EAE-resistant, Ac1-11 ECi MBP TCR Tg mice.
Cultured CD4 ؉ V␤8.2 ؊ Peripheral T Cells Gain Surface Expression of the MBP TCR. The detection of a large fraction of CD4 ϩ T cells with surface expression of endogenously rearranged TCR ␤ chains could reflect at least two phenomena. One possibility is that the rare CD4 ϩ V␤8.2 Ϫ T cells present in untreated MBP TCR Tg mice are induced to proliferate extensively, and their detection follows the expansion of a minor, preexisting population. On the other hand, MBP TCR ␤-chain expression may be altered in CD4 ϩ T cells from mice that were epicutaneously immunized and challenged with Ac1-11. The first possibility was rather improbable for two reasons. First, CD4 ϩ V␤8.2 Ϫ T cells from Ac1-11 ECi mice were not blasting, as assessed by examination of their side scatter͞forward scatter flow cytometry profile (data not shown). Second, the frequency of Ac1-11:I-A u complex reactive T cells would have to be high among the few T cells lacking expression of the Tg MBP TCR for such a massive expansion to occur upon challenge. Most importantly, we observed that sorted CD4 ϩ V␤8.2 Ϫ T cells from spleen͞lymph nodes of Ac1-11 ECi mice acquired a V␤8.2 ϩ surface phenotype after overnight incubation at 37°C in complete media in the absence of antigen or of any exogenous cytokines (Fig. 2 A-C) . By 48 h of culture, most cells were V␤8.2 ϩ and, remarkably, were positive when stained with the MBP TCR-specific 3H12 clonotypic mAb (Fig. 2 D and E) , indicating that ex vivo incubation at physiological temperature induced them to express the complete MBP ␣␤ TCR on their surface. We also observed that, over time, the CD4 ϩ V␤8.2 Ϫ population increased with concomitant decrease in the CD4 ϩ V␤8.2 ϩ population (Fig. 2F) . The data are most compatible with the idea that MBP TCR ␤-chain expression is repressed in peripheral CD4 ϩ H57 ϩ V␤8.2 Ϫ T cells from Ac1-11 ECi mice and, therefore, that these cells have undergone TCR revision in vivo.
To determine whether the repertoire of endogenously rearranged TCR ␤ chains expressed by CD4 ϩ V␤8.2 Ϫ T cells was diverse or rather restricted, we first performed flow cytometrycoupled immunostaining using a panel of anti-V␤-specific mAbs.
The results showed that multiple variable domains were used by the ␤ chain of endogenous origin in CD4 ϩ T cells with revised TCR from Ac1-11 ECi mice. Fig. 2G shows, for instance, that the V␤3, V␤4, V␤6, V␤10, and V␤14 domains were all used by substantial fractions of peripheral CD4 ϩ T cells from Ac1-11 ECi mice. Thus, in CD4 ϩ V␤8.2 Ϫ T cells, distinct TCR ␤ chains could be endogenously synthesized and used to form TCRs able to traffic intracellularly and get expressed on the cell surface. Expression of endogenous V␤ chains was further confirmed by detection of transcripts (data not shown).
CD4 ؉ V␤8.2 ؊ T Cells Express the RAG1 and RAG2 Proteins. Because the TCR gene rearrangement process requires both rag1 and rag2 gene products for sequence-specific DNA recognition and DNA cleavage and postcleavage functions (14, 15) , we examined whether we could detect RAG expression in CD4 ϩ T cells from Ac1-11 ECi mice that had acquired expression of endogenously rearranged TCR ␤ chains. We carried out RAG1-and RAG2-specific Western blot analysis of lysates from sorted CD4 ϩ T cells isolated from Ac1-11 ECi mice and of thymic and splenic cells from unmanipulated animals as controls. Although WT spleen cells and thymocytes were respectively negative and positive for RAG protein expression, peripheral CD4 ϩ V␤8.2 Ϫ T cells from the same mice were found to express substantial amounts of RAG1 and RAG2 proteins (Fig. 3A) . CD4 ϩ V␤8.2 ϩ T cells from Ac1-11 ECi mice, however, showed either no expression or, occasionally, trace amounts of RAG proteins (data not shown). There were rare CD4 ϩ V␤8.2 Ϫ T cell samples with detectable expression of RAG1 but not RAG2. RAG protein expression was typically observed for CD4 ϩ V␤8.2 Ϫ T cell samples from one-third to half of disease-resistant Ac1-11 ECi mice analyzed at a given time point. In contrast, spleen͞lymph node cells from MOG-ECi mice or unmanipulated MBP TCR Tg mice remained negative for RAG1͞2 protein expression (Fig. 3A) . These observations demonstrate that expression of the RAG proteins, which is turned off upon intrathymic positive selection and is normally absent in mature peripheral T lymphocytes (16, 17) , was induced in peripheral CD4 ϩ T cells that surface-express endogenously rearranged TCR ␤ chains in Ac1-11 ECi mice. ϩ epicutaneously immunized T cells showed signs of protection, with a greater resistance in the case of the CD4 ϩ V␤8.2 Ϫ T cell transfer (Fig. 3B) . Thus, although CD4 ϩ V␤8.2 Ϫ T cells seemed to have a slightly enhanced suppression potential under the conditions used, CD4 ϩ V␤8.2 ϩ T cells were protective as well. That is, there was no strict dependence on receptor revision for purified CD4 T cells from Ac1-11 mice to confer disease resistance upon adoptive transfer. To further examine whether receptor revision is required for protective activity, we turned to a more stringent assay. We used MBP TCR Tg rag2 Ϫ/Ϫ mice that exhibit spontaneous EAE and a fulminate disease course; all such mice develop severe clinical signs by 5 weeks of age and succumb very rapidly (ref. 5; unpublished data). We reasoned that if receptor revision was a requirement for ECi treatment to confer protection, we would repeatedly fail to observe any protection against EAE in epicutaneously immunized MBP TCR Tg rag2 Ϫ/Ϫ mice whose T cells are devoid of any V(D)J rearrangement potential. Conversely, the detection of disease resistance in such mice would strongly argue against a true requirement for receptor revision in order for ECi-induced protection to occur. We observed that two of eight Ac1-11 ECi MBP TCR Tg rag2 Ϫ/Ϫ mice remained free of clinical signs of disease over the time of observation (up to 3 months). In contrast, all mice died rapidly from EAE when epicutaneously immunized with MOG 35-55 (Table 1 ). The data support the notion that the ECi-induced protection against disease does not depend on TCR revision. Ϫ T cells from Ac1-11 ECi mice displayed augmented expression of CD44 and reduced expression levels of L-selectin (CD62L) (Fig. 3C) . CD4 ϩ V␤8.2 ϩ T cells from Ac1-11 ECi mice also displayed modified CD44 and CD62L expression (data not shown). This phenotype is reminiscent of that of antigen-experienced mouse T lymphocytes (18) (Fig. 3C ).
Peripheral T Cells with Revised TCR Do Not Require the Thymic
Microenvironment. Because developing thymocytes appear susceptible of modifying their receptor by de novo V(D)J rearrangements in response to self-determinants (19-21), a process often referred to as editing by reference to antigen-receptor modifications during B-cell maturation in bone marrow (22-26), we specifically asked whether the emergence of cells with revised TCR depended on the thymic compartment. To examine this issue, we sorted naïve CD4 ϩ V␤8.2 ϩ T cells from normal MBP TCR Tg mice and transferred them into regular B10.PL hosts that were thymectomized and sublethally irradiated (Fig. 4A) . FACS analysis showed that donor cells were detectable in the peripheral blood at 24 h posttransfer (Fig. 4B) . Six to ten days later, the recipient mice were epicutaneously immunized with Ac1-11 or a control peptide for 2 weeks and then immunized MBP TCR Tg rag2 Ϫ͞Ϫ mice whose T cells are devoid of V(D)J rearrangement capacity were epicutaneously immunized with Ac1-11 or MOG 35-55 (both 10 g), treated with Ac1-11 plus adjuvant for disease induction, and monitored for clinical signs of EAE over several months. with Ac1-11 plus adjuvant. Five of 10 mice died (data not shown). Two of the five disease-resistant mice clearly had a substantial fraction of T cells that were CD4 ϩ V␤8.2 Ϫ at 6 weeks postchallenge (Fig. 4C) . Upon isolation by sorting and incubation at 37°C, these cells switched again to a V␤8.2 ϩ 3H12 ϩ phenotype (data not shown). In contrast, we repeatedly failed to detect CD4 ϩ V␤8.2 Ϫ T cells in the few mice that could survive disease induction in the MOG 35-55 ECi control group (Fig. 4D) ϩ T cells gave a detectable proliferative response, they were clearly hyporesponsive when compared with the response of naïve MBP TCR Tg T cells (Fig. 4E ). This hyporesponsiveness was consistent with our previous observation that purified CD4 ϩ T cells from Ac1-11 ECi mice, which are able to transfer protection to naïve hosts, were only marginally responsive to specific stimulation in culture (13) . CD4 ϩ V␤8.2 Ϫ T cells, however, did not divide in response to Ac1-11 stimulation under the conditions used, although they could respond to anti-CD3 stimulation (data not shown). The data indicate that freshly isolated CD4 ϩ V␤8.2 Ϫ T cells from Ac1-11 ECi mice do not proliferate in response to the Ac1-11:I-A u complex in vitro.
Discussion
MBP TCR Tg mice epicutaneously immunized with only the cognate (Ac1-11) peptide before challenge for disease induction (Ac1-11 plus adjuvant) are protected against full EAE. Such resistance relies on the induction of CD4 ϩ suppressor T cells capable of conferring protection to naïve hosts upon adoptive transfer (13) . We document here the presence of a substantial fraction of peripheral blood, spleen, or lymph node CD4 ϩ T cells that lack expression of the Tg TCR ␤ chain (CD4 ϩ V␤8.2 Ϫ T cells) in Ϸ30-50% of Ac1-11 ECi MBP TCR Tg mice that are resistant to EAE. The emergence of CD4 ϩ V␤8.2 Ϫ cells required a double in vivo encounter with Ac1-11 because these cells were not detected in MBP TCR Tg mice that were epicutaneously immunized with Ac1-11 and not challenged for EAE induction. In addition, MBP TCR Tg mice epicutaneously immunized with MOG 35-55 (or ovalbumin) developed full EAE after Ac1-11-mediated disease induction and were devoid of peripheral CD4 ϩ V␤8. (20, (28) (29) (30) (31) . In our system, maintenance of TCR revision appeared to require factor(s) present in vivo, because acquisition of the 3H12 ϩ phenotype occurred relatively rapidly ex vivo. We speculate that the presence of Ac1-11 could be a contributing factor, as sorted CD4 ϩ V␤8.2 Ϫ T cells incubated with syngeneic antigen-presenting cells plus Ac1-11 in vitro did not gain the 3H12 ϩ phenotype (data not shown). Although RAG1 and RAG2 protein expression was often codetected in sorted CD4 ϩ V␤8.2 Ϫ T cells, it happened that only RAG1 was readily detectable. The reason for this difference is unclear, but, interestingly, a similar phenomenon has been reported for human mature CD4 ϩ CD3-low T cells that display RAG reexpression and initiate secondary V(D)J rearrangements (32) .
Sorted CD4 ϩ V␤8.2 Ϫ T cells from Ac1-11 ECi mice, that is, CD4 ϩ T cells bearing endogenously rearranged TCR ␤ chains, effectively mediate suppression of T cells that cause EAE in vivo. It is reasonable to assume that among CD4 ϩ V␤8.2 Ϫ T cells with revised TCR, there were many T cells with TCR synonymous to those expressed by the non-TCR Tg CD4 ϩ T cells that protect unmanipulated MBP TCR Tg mice from the spontaneous occurrence of disease (33) and that also display a diverse TCR repertoire (34) . Thus, the protective potential of CD4 ϩ V␤8.2 Ϫ T cells with revised TCR observed in vivo in transfer experiments is not unexpected. Indeed, the high incidence (Ϸ66%) of spontaneous EAE among MBP TCR Tg mice lacking only endogenous TCR ␤ chains (MBP TCR Tg C␤ Ϫ/Ϫ ) proved that cells with high suppressive potential in MBP TCR Tg mice are not subject to tight ␤-chain allelic exclusion (33) .
When we first observed TCR chain replacement in Ac1-11 ECi mice that were resistant to EAE induction, we wondered whether TCR revision was a requirement for protection. This scenario appears unlikely, because in a given group of simultaneously manipulated mice, at most one-third to one-half of EAEresistant mice displayed a substantial fraction of CD4 ϩ V␤8.2 Ϫ T cells at the time of analysis. The reason for this frequency is unclear, but it was not related to the sex or age of the mice (data not shown). It is possible that TCR revision occurs in most mice, but with a differential efficiency because of subtle variability in efficiency of Ac1-11 diffusion from the skin patch and͞or during s.c. immunization. More importantly, MBP TCR Tg rag2 Ϫ/Ϫ mice that normally display a fulminate disease course with 100% mortality by 5 weeks of age (5) could show long-term protection from EAE when epicutaneously immunized with Ac1-11.
In summary, the ECi of MBP TCR Tg mice with the CNS autoantigen Ac1-11 before immunization not only elicits T cells with dominant suppressor͞regulatory activity that confer protection against Ac1-11-induced EAE, but also causes CD4 ϩ T cells to repress surface expression of the autoreactive TCR ␤ chain and to express a broad repertoire of endogenously rearranged TCR ␤ chains because of RAG reexpression. The emergence of T cells with such revised TCRs was not dependent on the thymic compartment. Thus, the epicutaneous administration of pure autoantigens renders peripheral specific T cells susceptible to multiple mechanisms of tolerance in a nonmutually exclusive fashion.
